Inhalation of the endothelin-A receptor antagonist LU-135252 at various doses in experimental acute lung injury

J Cardiovasc Pharmacol. 2004 Nov:44 Suppl 1:S151-5. doi: 10.1097/01.fjc.0000166261.42723.b7.

Abstract

We studied the effects of the inhaled endothelin-A receptor antagonist LU-135252 at different doses on hemodynamics and gas exchange in an animal model of acute lung injury. Thirtysix piglets (27 +/- 1 kg) were anesthetized, mechanically ventilated (FiO2 1.0), and surfactant-depleted by repeated lung lavage. The animals were randomly assigned to receive either nebulized LU- 135252 for 30 minutes at a dose of 0.3 mg/kg (n = 12), or at a dose of 3.0 mg/kg (n = 12); n = 12 animals received no further treatment (Controls). Induction of acute lung injury decreased PaO2 from 566 +/- 8 mmHg to 53 +/- 2 mmHg (mean +/- SEM) and increased intrapulmonary shunt (QS/QT) from 13 +/- 1% to 57 +/- 2%. Inhalation of LU-135252 at either dose induced a significant and sustained increase in PaO2 (0.3 mg/kg: 349 +/- 39 mmHg; 3.0 mg/kg: 219 +/- 40 mmHg), and a significant decrease in QS/QT (0.3 mg/kg: 19 +/- 2%; 3.0 mg/kg: 27 +/- 3%) when compared with Controls (PaO2: 50 +/- 3 mmHg, QS/QT: 50 +/- 5%) (P < 0.05; values at 4 hours). Mean pulmonary artery pressure in LU-135252-treated animals (0.3 mg/kg: 31 +/- 2 mmHg; 3.0 mg/kg: 30 +/- 1 mmHg) was significantly lower than in Controls (40 +/- 2 mmHg), while there were no differences in mean arterial pressure and cardiac output. We conclude that inhalation of LU-135252 at either dose improved gas exchange and hemodynamics comparably, indicating that the lower dose was already sufficient to block the majority of endothelin-A receptors in ventilated regions of the injured lung.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Animals
  • Animals, Newborn
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Endothelin A Receptor Antagonists*
  • Hemodynamics / drug effects
  • Nebulizers and Vaporizers
  • Phenylpropionates / administration & dosage*
  • Pulmonary Gas Exchange / drug effects
  • Pyrimidines / administration & dosage*
  • Receptor, Endothelin A / metabolism
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome / metabolism
  • Respiratory Distress Syndrome / physiopathology
  • Respiratory System Agents / administration & dosage*
  • Swine
  • Time Factors

Substances

  • Endothelin A Receptor Antagonists
  • Phenylpropionates
  • Pyrimidines
  • Receptor, Endothelin A
  • Respiratory System Agents
  • darusentan